Salvage therapy
toxicity
EVENT, CONSOLIDATION
All patients are randomized upfront and receive one cycle of backbone salvage therapy with a standard HAM regimen. In patients aged 18–60 years, one cycle of cytarabine 3g/mDose reduction or interruption of quizartinib

Dose reduction or interruption of quizartinib in case of QTcF prolongation
The dose of quizartinib will be reduced by at least 50%without interruption of dosing.Following dose reduction, the quizartinib dose may be resumed at the previous level in the next cycle if the QTcF has decreased to within 30 ms of baseline or <450 ms.Quizartinib dosing will be interrupted for up to 14 days.• If QTcF returns to within 30 ms of baseline or <450 ms within 14 days, quizartinib administration may be resumed at a reduced dose.If QTcF >500 ms occurs during the Induction or Consolidation Phases, and if no cause other than quizartinib can be identified, then during the maintenance phase, the dose of quizartinib cannot be escalated to 60 mg/day.
Subjects who experience QT interval prolongation of more than 480 ms corrected for heart rate (QTcF) will undergo dose interruption and/or reduction of quizartinb and will be monitored closely by ECGs, performed twice weekly for the first week of the QTcF prolongation and then weekly thereafter until the QTcF prolongation is resolved (Table In the event of significant toxicity grade 3 or 4, dosing must be interrupted, delayed, and/or reduced by at least 50% [